Engelmann D - Search Results

1

Epigenetic factor EPC1 is a master regulator of DNA damage response by interacting with E2F1 to silence death and activate metastasis-related gene signatures.

Wang Y, Alla V, Goody D, Gupta SK, Spitschak A, Wolkenhauer O, Pützer BM, Engelmann D. Wang Y, et al. Among authors: engelmann d. Nucleic Acids Res. 2016 Jan 8;44(1):117-33. doi: 10.1093/nar/gkv885. Epub 2015 Sep 8. Nucleic Acids Res. 2016. PMID: 26350215 Free PMC article.

2

E2F1 in melanoma progression and metastasis.

Alla V, Engelmann D, Niemetz A, Pahnke J, Schmidt A, Kunz M, Emmrich S, Steder M, Koczan D, Pützer BM. Alla V, et al. Among authors: engelmann d. J Natl Cancer Inst. 2010 Jan 20;102(2):127-33. doi: 10.1093/jnci/djp458. Epub 2009 Dec 21. J Natl Cancer Inst. 2010. PMID: 20026813

3

Translating DNA damage into cancer cell death-A roadmap for E2F1 apoptotic signalling and opportunities for new drug combinations to overcome chemoresistance.

Engelmann D, Pützer BM. Engelmann D, et al. Drug Resist Updat. 2010 Aug-Oct;13(4-5):119-31. doi: 10.1016/j.drup.2010.06.001. Epub 2010 Aug 1. Drug Resist Updat. 2010. PMID: 20675184 Review.

4

The dark side of E2F1: in transit beyond apoptosis.

Engelmann D, Pützer BM. Engelmann D, et al. Cancer Res. 2012 Feb 1;72(3):571-5. doi: 10.1158/0008-5472.CAN-11-2575. Cancer Res. 2012. PMID: 22298593 Review.

5

E2F1 confers anticancer drug resistance by targeting ABC transporter family members and Bcl-2 via the p73/DNp73-miR-205 circuitry.

Alla V, Kowtharapu BS, Engelmann D, Emmrich S, Schmitz U, Steder M, Pützer BM. Alla V, et al. Among authors: engelmann d. Cell Cycle. 2012 Aug 15;11(16):3067-78. doi: 10.4161/cc.21476. Epub 2012 Aug 8. Cell Cycle. 2012. PMID: 22871739 Free PMC article.

6

E2F1 apoptosis counterattacked: evil strikes back.

Pützer BM, Engelmann D. Pützer BM, et al. Among authors: engelmann d. Trends Mol Med. 2013 Feb;19(2):89-98. doi: 10.1016/j.molmed.2012.10.009. Epub 2012 Dec 5. Trends Mol Med. 2013. PMID: 23219173 Review.

7

Kinetic modeling-based detection of genetic signatures that provide chemoresistance via the E2F1-p73/DNp73-miR-205 network.

Vera J, Schmitz U, Lai X, Engelmann D, Khan FM, Wolkenhauer O, Pützer BM. Vera J, et al. Among authors: engelmann d. Cancer Res. 2013 Jun 15;73(12):3511-24. doi: 10.1158/0008-5472.CAN-12-4095. Epub 2013 Feb 27. Cancer Res. 2013. PMID: 23447575

8

LncRNA-SLC16A1-AS1 induces metabolic reprogramming during Bladder Cancer progression as target and co-activator of E2F1.

Logotheti S, Marquardt S, Gupta SK, Richter C, Edelhäuser BAH, Engelmann D, Brenmoehl J, Söhnchen C, Murr N, Alpers M, Singh KP, Wolkenhauer O, Heckl D, Spitschak A, Pützer BM. Logotheti S, et al. Among authors: engelmann d. Theranostics. 2020 Jul 29;10(21):9620-9643. doi: 10.7150/thno.44176. eCollection 2020. Theranostics. 2020. PMID: 32863950 Free PMC article.

9

Functional interplay between E2F1 and chemotherapeutic drugs defines immediate E2F1 target genes crucial for cancer cell death.

Engelmann D, Knoll S, Ewerth D, Steder M, Stoll A, Pützer BM. Engelmann D, et al. Cell Mol Life Sci. 2010 Mar;67(6):931-48. doi: 10.1007/s00018-009-0222-0. Epub 2009 Dec 15. Cell Mol Life Sci. 2010. PMID: 20013022 Free PMC article.

10

Hybrid modeling of the crosstalk between signaling and transcriptional networks using ordinary differential equations and multi-valued logic.

Khan FM, Schmitz U, Nikolov S, Engelmann D, Pützer BM, Wolkenhauer O, Vera J. Khan FM, et al. Among authors: engelmann d. Biochim Biophys Acta. 2014 Jan;1844(1 Pt B):289-98. doi: 10.1016/j.bbapap.2013.05.007. Epub 2013 May 18. Biochim Biophys Acta. 2014. PMID: 23692959

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

55 results

Search Page

Filters